76
Views
1
CrossRef citations to date
0
Altmetric
Image Focus

The challenging management of cardiac involvement in systemic sarcoidosis

, , , , , , , , & show all
Pages 846-847 | Received 21 Jun 2021, Accepted 11 Jan 2022, Published online: 24 Jan 2022
 

Abstract

A 34 year-old young man came to our attention after an occasional finding of complete AV block. We made the diagnosis of systemic sarcoidosis with cardiac involvement through an FDG-PET even with a normal CMR. We started corticosteroid therapy and we decided to follow-up the patient through an implantable loop recorder (ILR). Beyond an initial regression of the AV block, after 8 months the ILR revealed AV block and pauses more than 3 s during the day; a new FDG-PET evidenced FDG uptake in new areas of left ventricle. Hence we started infliximab and implanted a dual chamber ICD.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Figure 1. FDG-PET showing systemic localization of granulomas (Panel A), FDG cardiac uptake within the heart (Panel B), only few lung FDG uptake persistence after corticosteroid therapy (Panel C), no more cardiac uptake (Panel D).

Figure 1. FDG-PET showing systemic localization of granulomas (Panel A), FDG cardiac uptake within the heart (Panel B), only few lung FDG uptake persistence after corticosteroid therapy (Panel C), no more cardiac uptake (Panel D).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.